Multi-omics tumor profiling technologies to develop precision medicine in multiple myeloma

Area of Science:

• Hematologic oncology
• Genomics and personalized medicine

Background:

• Multiple myeloma (MM) is the second most common hematologic cancer, characterized by abnormal plasma cell accumulation.
• Despite therapeutic advances, drug resistance and relapse remain significant challenges in MM patient mortality.
• The molecular underpinnings of MM are not fully elucidated, contributing to treatment complexities.

Purpose of the Study:

• To review current therapeutic strategies for multiple myeloma.
• To highlight the role of high-throughput omics technologies in understanding MM.
• To discuss the integration of omics data for personalized medicine in MM.

Main Methods:

• Review of current literature on multiple myeloma treatments.
• Analysis of the application of omics technologies (genomics, transcriptomics, epigenomics, proteomics, metabolomics) in MM research.
• Examination of data integration strategies combining omics and clinical data.

Main Results:

• Omics technologies provide deep insights into MM heterogeneity and molecular mechanisms.
• Integration of multi-omics data with clinical histories enables risk stratification and treatment response prediction.
• Personalized predictive models are emerging as crucial for optimizing MM patient care.

Conclusions:

• Omics-driven personalized medicine represents the future of multiple myeloma treatment.
• Accurate risk stratification and treatment selection can be achieved through integrated omics data.
• Continued advancements in omics and data analysis will further improve survival and quality of life for MM patients.